The results indicated that KRAS expression was significantly lower in tumour tissue than in tissue obtained from normal subjects, providing evidence that KRAS gene mutation is an independent risk factor for the prognosis of colorectal cancer patients. The gene discussed is KRAS; the disease is neoplasm.